Some unlikely good Samaritans are going out of their way to help AbbVie (NYSE: ABBV) and Allergan (NYSE: AGN) complete the $63 billion merger deal the giant drugmakers announced last June. To appease antitrust regulators, AstraZeneca (NYSE: AZN) will take back control of an experimental psoriasis drug, and Nestle will acquire a gastrointestinal medication from Allergan. Hello again Allergan was developing a monoclonal antibody that inhibits interleukin 23 (IL-23) called brazikumab for the treatment of Crohn's disease and ulcerative colitis. AbbVie recently launched its own IL-23 inhibitor, risankizumab, under the brand name Skyrizi for the treatment of psoriasis. Image source: Getty Images. Allergan had licensed brazikumab from AstraZeneca; now, it will return the antibody to the big British pharmaceutical company. At the moment, brazikumab and Skyrizi are both in late-stage clinical trials for the treatment of Crohn's disease and ulcerative colitis. More than just cocoa You're probably more familiar with the Swiss food conglomerate's packaged food brands, but Nestle is also a leading player in the growing medical nutrition space. Nestle will acquire Zenpep from Allergan for an undisclosed sum, adding it to its growing line of nutritional therapies designed for specific medical conditions. Zenprep is a collection of pancreatic enzymes that is especially useful for cystic fibrosis (CF) patients. Since Nestle already markets nutritional therapies for CF and a wide range of other disorders, Zenprep should fit comfortably in its portfolio. 10 stocks we like better than AllerganWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Allergan wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.Source